Interaction between EBV-specific CD8+ T-cell recovery and EBV reactivation after SCT
. | Time points in months after SCT* . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 2 . | 3 . | 6 . | 9 . | 12 . | 18 . | 24 . | ||||||
| No. of patients at risk† | 60 | 54 | 40 | 32 | 26 | 18 | 9 | ||||||
| No. of patients with complete virologic and immunologic data‡ | 35 | 37 | 30 | 22 | 17 | 14 | 3 | ||||||
| No. (%) of patients with detectable EBV-specific CD8+ T cells | 7 (20) | 13 (35) | 22 (73) | 16 (73) | 15 (88) | 12 (86) | 3 (100) | ||||||
| No. (%) of patients with EBV reactivation | 11 (31) | 15 (41) | 6 (20) | 4 (18) | 2 (12) | 1 (7) | 0 (0) | ||||||
. | Time points in months after SCT* . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 2 . | 3 . | 6 . | 9 . | 12 . | 18 . | 24 . | ||||||
| No. of patients at risk† | 60 | 54 | 40 | 32 | 26 | 18 | 9 | ||||||
| No. of patients with complete virologic and immunologic data‡ | 35 | 37 | 30 | 22 | 17 | 14 | 3 | ||||||
| No. (%) of patients with detectable EBV-specific CD8+ T cells | 7 (20) | 13 (35) | 22 (73) | 16 (73) | 15 (88) | 12 (86) | 3 (100) | ||||||
| No. (%) of patients with EBV reactivation | 11 (31) | 15 (41) | 6 (20) | 4 (18) | 2 (12) | 1 (7) | 0 (0) | ||||||
Patients were evaluated in time intervals, starting from each indicated time point until the next time point. The time interval from 24 months onward was 6 months.
Numbers of patients at risk per time interval: defined by the numbers of patients who survived during each time interval.
Numbers of patients with complete virologic and immunologic data per time interval: defined by (1) availability of data on EBV-specific CD8+ T cells at the initial time point and (2) follow-up for EBV reactivation from the initial time point until the next time point.